Study guide
1.2 Sepsis, Sepsis Six Protocol & Septic Shock
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
1.2 Sepsis, Sepsis Six Protocol & Septic Shock
Key Takeaways Explain This Topic AI
The Sepsis-3 consensus defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, objectified by an acute change in total SOFA score of ≥2 points.
Under NICE NG253 (November 2025), an adult with suspected infection and NEWS2 of 7 or more is high risk: FY2-or-above review, venous lactate and blood cultures, IV antibiotics within 1 hour, and IV balanced crystalloid in 250 mL boluses up to 1,000 mL.
Septic shock is clinically defined by persistent hypotension requiring vasopressors to maintain MAP ≥65 mmHg AND serum lactate >2 mmol/L despite adequate fluid resuscitation.
Noradrenaline is the first-line vasopressor of choice in septic shock; balanced crystalloid resuscitation should avoid large unbuffered saline infusions to prevent hyperchloraemic metabolic acidosis.
Last updated: October 2026
Sepsis, Sepsis Six Protocol & Septic Shock
Sepsis represents one of the leading causes of acute in-hospital deterioration and mortality in the National Health Service (NHS). Rapid recognition and time-critical delivery of basic resuscitation bundles within the first hour markedly reduce mortality and progression to multi-organ failure.
Sepsis-3 Definitions & Pathophysiology
Sepsis is defined by the Sepsis-3 (Third International Consensus Definitions for Sepsis and Septic Shock) criteria. UK early management follows NICE NG253 ( Suspected sepsis in people aged 16 or over , published November 2025, updated 2026) , which replaced NG51 together with NG254 (under 16s) and NG255 (pregnant or recently pregnant people):
Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection.
Organ Dysfunction: An acute change in total Sequential Organ Failure Assessment (SOFA) score of ≥2 points attributable to the infectious insult. An acute SOFA increase of ≥2 points is associated with an in-hospital mortality of more than 10%.
The SOFA Score Domains
Respiration: PaO2/FiO2 ratio (hypoxaemia).
Coagulation: Platelet count (thrombocytopenia from consumption).
Liver: Serum bilirubin elevation.
Cardiovascular: Mean arterial pressure (MAP) or requirement for vasopressor support.
Central Nervous System: Glasgow Coma Scale (GCS) score drop.
Renal: Serum creatinine rise or acute oliguria.
Bedside Risk Stratification: qSOFA & NEWS2
The quick SOFA (qSOFA) bedside assessment tool identifies non-ICU patients with suspected infection at high risk of deterioration (score ≥2):
- Respiratory Rate: ≥ 22 breaths/min
- Altered Mentation: GCS < 15
- Systolic Blood Pressure: ≤ 100 mmHg
In NHS practice, qSOFA is a teaching and research tool rather than the escalation trigger. NICE NG253 stratifies adults with suspected or confirmed infection using the National Early Warning Score 2 (NEWS2) , interpreted with clinical judgement: 7 or more = high risk , 5–6 = medium risk , 1–4 = low risk , 0 = very low risk of severe illness or death from sepsis. If a single parameter scores 3, request a high-priority review by a clinician with acute-care competencies (FY2 or above) to decide the risk level. Mottled or ashen skin, a non-blanching rash, or other causes for concern can raise the risk above that suggested by NEWS2 alone.
NICE NG253 Risk Bands & the "Sepsis Six"
NICE NG253 links each NEWS2 band to time-critical actions:
NEWS2 band Risk of severe illness or death Key NICE NG253 actions
7 or more (or a single parameter of 3 confirmed as high risk on review) High Urgent review by a clinician at FY2 level or above; venous blood gas with glucose and lactate, blood cultures, FBC, CRP, U&Es, creatinine, LFTs and clotting; broad-spectrum IV antibiotics within 1 hour of calculating NEWS2; IV fluid within 1 hour unless contraindicated; involve the senior decision-maker, and the consultant and critical care if there is no response within 1 hour of any intervention
5–6 Medium The same blood tests; FY2-or-above review of the patient and venous lactate within 1 hour; antibiotics may be deferred for up to 3 hours while a more specific diagnosis is sought; treat as high risk if there is hypoperfusion (lactate over 2 mmol/L or acute kidney injury)
- 1–4 Low Clinical assessment, look for alternative diagnoses and the source, and safety-net
- 0 Very low Manage the infection on its own merits
NG253 (2026 update) also suggests considering procalcitonin testing, alongside standard tests, in adults at medium or high risk.
Fluid Resuscitation Under NG253
Use an isotonic crystalloid, preferably a balanced solution such as Hartmann's (0.9% saline only if a balanced solution is not available).
Give an initial 250 mL bolus over 10–15 minutes , reassess after each bolus, and give further 250 mL boluses up to 1,000 mL in total (including fluid already given). If the person has not improved after 1,000 mL, get advice from a senior clinical decision-maker.
NICE reduced the first bolus from 500 mL to 250 mL in 2025. The international Surviving Sepsis Campaign still describes up to 30 mL/kg in the first 3 hours, but UK exam answers follow NICE.
The UK Sepsis Trust "Sepsis Six"
The UK Sepsis Trust bundle, whose clinical tools were updated to match NICE, is the bedside checklist for high-risk patients and should be delivered within the first hour:
- Step Action Practical points
- 1 Inform a senior clinician Confirm sepsis, consider alternative diagnoses and agree any treatment limits
- 2 Give oxygen if required Titrate to SpO2 94–98% (88–92% if at risk of hypercapnic respiratory failure)
3 Send bloods, including cultures Blood cultures (ideally before antibiotics but without delaying them), venous blood gas with lactate and glucose, FBC, U&Es, CRP, LFTs and clotting; sample other sites (urine, sputum, wound)
4 Consider IV antibiotics and source control Broad-spectrum, per local guideline, within 1 hour for high-risk patients; call surgeons or radiology early for drainable sources
5 Consider IV fluids Balanced crystalloid in 250 mL boluses with reassessment, up to 1,000 mL before senior review
6 Continue monitoring NEWS2, hourly urine output (catheterise if needed; target above 0.5 mL/kg/h) and repeat lactate; escalate if not improving
Important
Avoid Large Volumes of 0.9% Saline: Large volumes of 0.9% sodium chloride cause hyperchloraemic metabolic acidosis and are associated with more renal replacement therapy. NICE NG253 prefers balanced crystalloids (Hartmann's solution or Plasma-Lyte) for sepsis resuscitation.
Septic Shock: Definition & Hemodynamic Resuscitation
Septic shock is a clinical subset of sepsis wherein underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality (>40%).
- Clinical Criteria for Septic Shock
- Persisting hypotension requiring vasopressors to maintain a Mean Arterial Pressure (MAP) ≥ 65 mmHg , AND
Serum lactate > 2.0 mmol/L (18 mg/dL) despite adequate volume resuscitation.
Hemodynamic Targets & Drug Selection
Target MAP: Maintain MAP ≥ 65 mmHg to ensure adequate vital organ perfusion pressure (cerebral, coronary, and renal).
First-Line Vasopressor: Noradrenaline (norepinephrine) is the drug of choice. It acts predominantly as a potent alpha-1 adrenergic agonist to restore systemic vascular resistance, with modest beta-1 inotropic activity. It is ideally given through a central venous line; NICE NG253 accepts peripheral administration after a shared decision, following local policies on drug, dose, concentration and monitoring, so that treatment is not delayed.
Second-Line Vasopressor: Vasopressin (at a fixed dose of 0.03 units/min) can be added to noradrenaline to either raise MAP or reduce noradrenaline dosage requirements.
Inotrope Selection: If myocardial dysfunction persists with low cardiac output and hypoperfusion despite adequate volume and MAP, add an inotrope such as dobutamine .
Corticosteroids: Intravenous hydrocortisone (200 mg/day) is suggested for septic shock with an ongoing vasopressor requirement (Surviving Sepsis Campaign 2021 example: noradrenaline 0.25 µg/kg/min or more for at least 4 hours).
Biomarkers & Serial Assessment
Serum Lactate: Reflects anaerobic glycolysis secondary to tissue hypoperfusion, mitochondrial dysfunction, and accelerated aerobic glycolysis driven by adrenergic stimulation. Measuring serial lactate clearance is vital: failure to clear lactate by ≥20% every 2 hours during active resuscitation strongly correlates with worsening multi-organ dysfunction and death.
Procalcitonin (PCT): Produced by parenchymal tissues in response to bacterial endotoxins and pro-inflammatory cytokines (IL-1β, TNF-α). Useful for confirming bacterial aetiology and guiding antibiotic discontinuation decisions (antimicrobial stewardship).
C-Reactive Protein (CRP): Acute-phase reactant synthesized by the liver in response to IL-6. Highly sensitive for systemic inflammation, though non-specific; useful for tracking therapeutic response over 48–72 hours.